Antibody may improve plaque psoriasis

Article

A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.

Related Videos
Related Content

Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Eczema Resources for Your Patients: Week 1

October 2nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD

October 1st 2023

Spotlighting Advances in Atopic Dermatitis Research and Prevention Strategies

October 1st 2023

Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Eczema Resources for Your Patients: Week 1

October 2nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD

October 1st 2023

Spotlighting Advances in Atopic Dermatitis Research and Prevention Strategies

October 1st 2023

Risankizumab Efficacious in Patients With Concomitant Psoriasis and HIV, Study Reports

October 2nd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Eczema Resources for Your Patients: Week 1

October 2nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD

October 1st 2023

Spotlighting Advances in Atopic Dermatitis Research and Prevention Strategies

October 1st 2023
© 2023 MJH Life Sciences

All rights reserved.